SCHEMBL6401822

SCHEMBL6401822

CC(C)(C1C=C(C2CCCCCC2)c2ccccc21)C1C=C(C2CCCCCC2)c2ccccc21

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 2/20 0.41
PTPRC P08575 1/20 0.41
PTPRF P10586 1/20 0.41
CDC25B P30305 1/20 0.41
PTGS2 P35354 1/20 0.39
BCHE P06276 1/20 0.37
ACHE P22303 1/20 0.37
PTPN5 P54829 3/20 0.32
PTPN2 P17706 1/20 0.32
ADRA2A P08913 2/20 0.32
ADRA2B P18089 1/20 0.32
ADRA2C P18825 1/20 0.32
USP2 O75604 1/20 0.32
CYP1A2 P05177 1/20 0.32
HTR1A P08908 1/20 0.32
CYP2D6 P10635 1/20 0.32
CHRM1 P11229 1/20 0.32
CYP2C9 P11712 1/20 0.32
DRD1 P21728 1/20 0.32
TBXA2R P21731 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6402365 1.00 PTPN1 (0.41) PTPN1PTPRCPTPRFCDC25BPTGS2
SCHEMBL6403293 0.98 PTPN1 (0.39) PTPN1PTPRCPTPRFCDC25BPTGS2
SCHEMBL6406806 0.92 CHRM2 (0.31) PTPN1PTPRCPTPRFCDC25BCYP1A2
SCHEMBL6400780 0.74 IDO1 (0.36) CDC25BBCHEACHEHTTIDO1
SCHEMBL6402510 0.74 BCHE (0.37) PTGS2BCHEACHECYP2D6TSHR
SCHEMBL6401023 0.73 PTPN1 (0.42) PTPN1PTPRCPTPRFCDC25BPTGS2
SCHEMBL6403734 0.73 PTPN1 (0.42) PTPN1PTPRCPTPRFCDC25BPTGS2
SCHEMBL6401047 0.72 BCHE (0.35) BCHEACHEIDO1TDO2
SCHEMBL6408453 0.72 SLC6A3 (0.34) CYP1A2CYP2D6SLC6A4HTT
SCHEMBL6406800 0.71 PTPN1 (0.41) PTPN1PTPRCPTPRFCDC25BPTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6844288-B2 Process for the preparation of ligands for metallogene catalysts BASELL POLYOLEFINE GMBH (DE) 2005-01-18 US disclosed
US-20030158356-A1 Process for the preparation of substantially amorphous alpha-olefin polymers and compositions containing them and process for the preparation of bridged ligand EQUISTAR CHEMICALS, LP 2003-08-21 US disclosed
US-20020169260-A1 Process for the preparation of ligands for metallocene catalysts RESCONI LUIGI (IT) 2002-11-14 US disclosed
US-6423796-B1 COORDINATION CATALYST BASEL TECHNOLOGY COMPANY BV (NL) 2002-07-23 US disclosed
WO-2000001738-A9 PROCESS FOR THE PREPARATION OF SUBSTANTIALLY AMORPHOUS ALPHA-OLEFIN POLYMERS, COMPOSITIONS CONTAINING THEM AND PROCESS FOR THE PREPARATION OF BRIDGED LIGAND MONTELL TECHNOLOGY COMPANY BV (NL) 2000-07-27 WO disclosed
EP-1017729-A2 PROCESS FOR THE PREPARATION OF SUBSTANTIALLY AMORPHOUS ALPHA-OLEFIN POLYMERS, COMPOSITIONS CONTAINING THEM AND PROCESS FOR THE PREPARATION OF BRIDGED LIGAND Montell Technology Company bv (NL) 2000-07-12 EP disclosed
WO-2000001738-A2 PROCESS FOR THE PREPARATION OF SUBSTANTIALLY AMORPHOUS ALPHA-OLEFIN POLYMERS, COMPOSITIONS CONTAINING THEM AND PROCESS FOR THE PREPARATION OF BRIDGED LIGAND MONTELL TECHNOLOGY COMPANY BV (NL) 2000-01-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030158356-A1 Process for the preparation of substantially amorphous alpha-olefin polymers and compositions containing them and process for the preparation of bridged ligand MACF1, SDC1, SDC2 PTPN1 2634/4885PTPRC 1196/4885PTPRF 1938/4885
US-20020169260-A1 Process for the preparation of ligands for metallocene catalysts SDC1, SDC2, SDC4 PTPN1 2663/4885PTPRC 733/4885PTPRF 1665/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.